$1.2 Billion is the total value of Sofinnova Investments, Inc.'s 61 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 47.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KRTX | Buy | Karuna Therapeutics Inc | $262,271,000 | +5.9% | 2,073,124 | +6.1% | 21.84% | +16.2% |
| NTRA | Natera Inc | $109,969,000 | -12.9% | 3,102,960 | 0.0% | 9.16% | -4.4% | |
| Cincor Pharma Inc | $105,013,000 | +7.4% | 5,573,949 | 0.0% | 8.74% | +17.9% | ||
| AVTE | Aerovate Therapeutics Inc | $58,748,000 | -14.7% | 3,758,686 | 0.0% | 4.89% | -6.4% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $46,464,000 | -20.8% | 499,824 | 0.0% | 3.87% | -13.1% | |
| VERA | Vera Therapeutics Inccl a | $43,299,000 | -42.1% | 3,181,442 | 0.0% | 3.61% | -36.4% | |
| XLV | New | Health Care Select Sector SPDR Fundput | $38,472,000 | – | 300,000 | +100.0% | 3.20% | – |
| YMAB | Y-mAbs Therapeutics Inc | $33,199,000 | +27.4% | 2,194,278 | 0.0% | 2.76% | +39.8% | |
| MRK | New | Merck & Co Inc | $32,909,000 | – | 360,961 | +100.0% | 2.74% | – |
| NVO | New | Novo-Nordisk A Sadr | $30,518,000 | – | 273,873 | +100.0% | 2.54% | – |
| XBI | Buy | SPDR S&P Biotech ETFput | $29,708,000 | +65.3% | 400,000 | +100.0% | 2.47% | +81.4% |
| UTHR | Sell | United Therapeutics Corp | $25,067,000 | -29.9% | 106,379 | -46.6% | 2.09% | -23.0% |
| BMRN | Buy | Biomarin Pharmaceutical Inc | $24,994,000 | +83.6% | 301,605 | +70.8% | 2.08% | +101.5% |
| RETA | Buy | Reata Pharmaceuticals Inccl a | $23,821,000 | +20.7% | 783,851 | +30.1% | 1.98% | +32.4% |
| VRTX | Sell | Vertex Pharmaceuticals Inc | $21,066,000 | -15.0% | 74,758 | -21.3% | 1.75% | -6.8% |
| AZN | Sell | AstraZeneca PLCsponsored adr | $20,902,000 | -43.1% | 316,360 | -42.9% | 1.74% | -37.6% |
| RGNX | Buy | Regenxbio Inc | $19,183,000 | -5.9% | 776,624 | +26.5% | 1.60% | +3.3% |
| INZY | Buy | Inozyme Pharm Inc | $17,436,000 | +110.2% | 3,655,308 | +80.2% | 1.45% | +130.5% |
| CTIC | Buy | CTI Biopharma Corp | $16,146,000 | +77.1% | 2,704,510 | +38.5% | 1.34% | +94.4% |
| CCXI | Buy | ChemoCentryx Inc | $15,776,000 | +9.7% | 636,659 | +11.0% | 1.31% | +20.3% |
| IRTC | New | iRhythm Technologies Inc | $15,350,000 | – | 142,091 | +100.0% | 1.28% | – |
| SNY | New | Sanofi SAsponsored adr | $14,118,000 | – | 282,200 | +100.0% | 1.18% | – |
| DXCM | Buy | Dexcom Inc | $14,093,000 | -31.6% | 189,092 | +369.6% | 1.17% | -24.9% |
| CYTK | Buy | Cytokinetics Inc | $12,603,000 | +443.9% | 320,780 | +409.6% | 1.05% | +496.6% |
| NXTC | Nextcure Inc | $12,558,000 | -3.3% | 2,671,856 | 0.0% | 1.05% | +6.1% | |
| IMTX | Buy | Immatics NV | $11,272,000 | +11.3% | 1,294,103 | +2.1% | 0.94% | +22.1% |
| RXDX | New | Prometheus Biosciences Inc | $10,908,000 | – | 386,395 | +100.0% | 0.91% | – |
| SRPT | Buy | Sarepta Therapeutics Inc | $9,838,000 | +41.7% | 131,245 | +47.7% | 0.82% | +55.4% |
| ZNTL | New | Zentalis Pharmaceuticals Inc | $9,228,000 | – | 328,397 | +100.0% | 0.77% | – |
| HZNP | Sell | Horizon Therapeutics PLC | $8,000,000 | -67.4% | 100,297 | -56.9% | 0.67% | -64.2% |
| SNDX | Sell | Syndax Pharmaceuticals Inc | $7,954,000 | -36.2% | 413,428 | -42.3% | 0.66% | -30.0% |
| OBSV | ObsEva SA | $7,647,000 | +6.6% | 4,749,623 | 0.0% | 0.64% | +17.1% | |
| ACET | Buy | Adicet Bio Inc | $7,568,000 | -9.0% | 518,379 | +24.5% | 0.63% | -0.2% |
| AKUS | Akouos Inc | $7,106,000 | -1.3% | 1,515,074 | 0.0% | 0.59% | +8.4% | |
| ISEE | Sell | Iveric Bio Inc | $6,282,000 | -63.4% | 653,047 | -36.1% | 0.52% | -59.9% |
| CCXI | New | ChemoCentryx Inccall | $6,195,000 | – | 250,000 | +100.0% | 0.52% | – |
| ARGX | New | argenx SEsponsored adr | $5,683,000 | – | 15,000 | +100.0% | 0.47% | – |
| BOLT | Bolt Biotherapeutics Inc | $5,619,000 | -25.5% | 2,754,437 | 0.0% | 0.47% | -18.3% | |
| TVTX | Sell | Travere Therapeutics Inc | $5,151,000 | -69.6% | 212,593 | -67.7% | 0.43% | -66.7% |
| IMGN | Sell | ImmunoGen Inc | $5,134,000 | -24.5% | 1,140,788 | -20.1% | 0.43% | -17.1% |
| SGEN | New | Seagen Inc | $4,936,000 | – | 27,894 | +100.0% | 0.41% | – |
| KDNY | New | Chinook Therapeutics Inc | $4,838,000 | – | 276,609 | +100.0% | 0.40% | – |
| XNCR | Sell | Xencor Inc | $4,329,000 | -40.8% | 158,164 | -42.3% | 0.36% | -35.0% |
| GERN | Buy | Geron Corp | $4,327,000 | +67.1% | 2,791,630 | +46.6% | 0.36% | +82.7% |
| NCNA | Nucana Biomedsponsored adr | $4,060,000 | -27.4% | 5,599,999 | 0.0% | 0.34% | -20.5% | |
| GRTX | Galera Therapeutics Inc | $4,009,000 | -45.4% | 3,083,712 | 0.0% | 0.33% | -40.0% | |
| Buy | Amylyx Pharmaceuticals Inc | $3,609,000 | +180.9% | 187,381 | +87.4% | 0.30% | +207.1% | |
| JNCE | Sell | Jounce Therapeutics Inc | $2,975,000 | -70.4% | 981,928 | -33.7% | 0.25% | -67.5% |
| AGEN | New | Agenus Inc | $1,848,000 | – | 952,742 | +100.0% | 0.15% | – |
| Nucana Biomedordinary shares | $1,740,000 | -27.4% | 2,400,000 | 0.0% | 0.14% | -20.3% | ||
| INBX | Sell | Inhibrx Inc | $1,679,000 | -85.4% | 147,935 | -71.3% | 0.14% | -83.9% |
| GERN | Geron Corpcall | $1,550,000 | +14.0% | 1,000,000 | 0.0% | 0.13% | +25.2% | |
| CLDX | New | Celldex Therapeutics Inc | $1,302,000 | – | 48,304 | +100.0% | 0.11% | – |
| PTGX | Sell | Protagonist Therapeutics Inccall | $791,000 | -83.3% | 100,000 | -50.0% | 0.07% | -81.6% |
| SYBX | Synlogic Inc | $661,000 | -52.1% | 574,972 | 0.0% | 0.06% | -47.6% | |
| PDSB | PDS Biotechnology Corporation | $521,000 | -41.0% | 142,635 | 0.0% | 0.04% | -35.8% | |
| FUSN | Fusion Pharmaceuticals Inc | $194,000 | -68.0% | 78,066 | 0.0% | 0.02% | -65.2% | |
| INSM | Buy | Insmed Inc | $145,000 | +15.1% | 7,370 | +37.3% | 0.01% | +20.0% |
| HRTX | Exit | Heron Therapeutics Inc | $0 | – | -11,060 | -100.0% | -0.01% | – |
| PTCT | Exit | PTC Therapeutics Inc | $0 | – | -3,480 | -100.0% | -0.01% | – |
| PODD | Exit | Insulet Corp | $0 | – | -1,066 | -100.0% | -0.02% | – |
| Exit | Mink Therapeutics Inc | $0 | – | -331,002 | -100.0% | -0.06% | – | |
| ICPT | Exit | Intercept Pharmaceuticals Inccall | $0 | – | -100,000 | -100.0% | -0.12% | – |
| PFE | Exit | Pfizer Inc | $0 | – | -49,378 | -100.0% | -0.19% | – |
| FULC | Exit | Fulcrum Therapeutics Inc | $0 | – | -229,509 | -100.0% | -0.41% | – |
| BCYC | Exit | Bicycle Therapeutics PLCadr | $0 | – | -163,559 | -100.0% | -0.54% | – |
| Exit | ChemoCentryx Inccall | $0 | – | -300,000 | -100.0% | -0.57% | – | |
| CMPI | Exit | Checkmate Pharmaceuticals Inc | $0 | – | -3,606,707 | -100.0% | -0.87% | – |
| PTGX | Exit | Protagonist Therapeutics Inc | $0 | – | -547,441 | -100.0% | -0.98% | – |
| GH | Exit | Guardant Health Inc | $0 | – | -239,995 | -100.0% | -1.21% | – |
| SRRA | Exit | Sierra Oncology Inc | $0 | – | -572,297 | -100.0% | -1.39% | – |
| ZTS | Exit | Zoetis Inc | $0 | – | -106,574 | -100.0% | -1.52% | – |
| IWM | Exit | iShares Russell 2000 ETFput | $0 | – | -150,000 | -100.0% | -2.34% | – |
| QQQ | Exit | Invesco QQQ Trust Series 1put | $0 | – | -175,000 | -100.0% | -4.82% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.